Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
216.13
+1.31 (+0.61%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
31
32
33
34
35
36
37
38
Next >
PreMarket Prep Recap: The 4 Stocks Dennis Dick Bought Yesterday
June 24, 2021
On Wednesday’s PreMarket Prep, co-hosts Joel Elconin and Dennis Dick discussed the bullish chart setups in several tech stocks. ...
Via
Benzinga
Why Lilly Shares Are Moving Thursday
June 24, 2021
Eli Lilly and Company (NYSE: LLY) shares are advancing solidly Thursday following an update the company provided on its Alzheimer's program. What Happened: Lilly, which...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 24, 2021
Gainers Aravive (NASDAQ:ARAV) stock moved upwards by 21.61% to $6.47 during Thursday's pre-market session. The company's market cap stands at $131.9 million. Arcus...
Via
Benzinga
Expert Ratings for Biogen
June 18, 2021
Biogen (NASDAQ:BIIB) has observed the following analyst ra...
Via
Benzinga
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
June 24, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ...
Via
Benzinga
Could Cassava Sciences Be a Millionaire-Maker Stock?
June 24, 2021
Can this biotech underdog develop an Alzheimer's drug investors can count on?
Via
The Motley Fool
Biogen Stock Dips As FDA Documents Outline Internal Strife Ahead Of Alzheimer's OK
June 23, 2021
Biogen stock skidded Wednesday after the company answered a series of questions surrounding its controversial Alzheimer's treatment, Aduhelm.
Via
Investor's Business Daily
Exposures
Product Safety
14 Biotech Stocks To Watch Over The Next 6 Months
June 23, 2021
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:...
Via
Benzinga
Netflix And Amazon Lead The Nasdaq Higher Tuesday
June 22, 2021
U.S. Indices continued higher Tuesday as the market rebounds from last week's weakness following a shift in the Fed's policy. ...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Why Biogen Isn't a Buy After Its Alzheimer's Drug Approval
June 20, 2021
Here's one longtime healthcare expert's perspective.
Via
The Motley Fool
Exposures
Product Safety
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
June 20, 2021
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal...
Via
Benzinga
Exposures
Product Safety
Could Biogen's Stunning Alzheimer's Drug Victory Only Be Temporary?
June 20, 2021
In theory, yes. Realistically, probably not.
Via
The Motley Fool
3 More Reasons Biogen's Alzheimer's Drug Will Underperform Wall Street Expectations
June 20, 2021
Beyond its lofty price tag, there are other impediments to big sales of aducanamab that the market largely ignored this week.
Via
The Motley Fool
Did This Company Just Win Big Because of Biogen?
June 20, 2021
Alzheimer's disease patients who take Aduhelm will need a lot of diagnostic scans, too. Imaging leader RadNet stands to benefit.
Via
The Motley Fool
Exposures
Product Safety
Biogen's Alzheimer's Drug Deals With CVS and Cigna: What Investors Should Know
June 19, 2021
One of these agreements could be more important than the other.
Via
The Motley Fool
2 Stocks That Could Be Winners in Alzheimer's Disease Along With Biogen
June 19, 2021
One is Biogen's partner. The other is a potential rival.
Via
The Motley Fool
Here's Why Sage Therapeutics Tanked This Week
June 19, 2021
The neuroscience-focused biotech company didn't give investors the result they wanted.
Via
The Motley Fool
Wall Street In Fives: Must Read Lists At Midday - Friday, June 18
June 18, 2021
Get caught up quickly on the top news and calls moving stocks with these
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For June 18, 2021
June 18, 2021
Upgrades According to JP Morgan, the prior rating for Orion Engineered Carbons SA (NYSE:
Via
Benzinga
Senator Joe Manchin Urges President Biden Not To Nominate Janet Woodcock As FDA Commissioner
June 18, 2021
While Senator Joe Manchin has been vocal on his opposition to Janet Woodcock as Biden’s choice for FDA commissioner, he spelled out detailed concerns in a letter to...
Via
Benzinga
Exposures
Product Safety
Is It Too Late to Buy Biogen Stock?
June 18, 2021
Probably not, but things could still get complicated.
Via
The Motley Fool
10 Biggest Price Target Changes For Friday
June 18, 2021
Piper Sandler raised Adobe Inc. (NASDAQ: ADBE) price target from $570 to $600. Adobe shares rose 3.3% to $569.50 in pre-market trading. SVB Leerink boosted Jazz...
Via
Benzinga
Why Did the FDA Approve Biogen's Alzheimer's Disease Drug After an Advisory Panel Recommended Against It?
June 18, 2021
The bottom line: The FDA can do what it wants to do.
Via
The Motley Fool
Exposures
Product Safety
AMD And Nvidia Lead The Nasdaq Higher Thursday
June 17, 2021
U.S. indices had a mixed day of trading following Wednesday's Fed announcement. The Fed raised its inflation outlook for 2021 an...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Biogen Commences Dosing In Late-Stage Systemic Lupus Erythematosus Study With BIIB059
June 17, 2021
Biogen Inc (NASDAQ: BIIB) has dosed the first patient in the TOPAZ-1 Phase 3 study evaluating BIIB059 in participants with active systemic lupus erythematosus (SLE...
Via
Benzinga
The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme
June 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,...
Via
Benzinga
Exposures
COVID-19
Biogen Discontinues Tau Antibody Program For Alzheimer's After Mid-Stage Study Flops
June 17, 2021
Biogen Inc (NASDAQ: BIIB) has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, of which one has just been canned. The...
Via
Benzinga
Best and Worst Russell 1000 Stocks So Far in June
June 16, 2021
Right at the midpoint of June, Biogen has been the top-performing Russell 1,000 stock month to date.
Via
Talk Markets
First Patient Set To Receive Biogen's Alzheimer's Drug: Reuters
June 16, 2021
A U.S. hospital on Wednesday will give the first infusion of Biogen Inc's (NASDAQ: BIIB) expensive, controversial Alzheimer's drug approved a week ago....
Via
Benzinga
Cramer Shares His Thoughts On Vertex Pharma, Snap And More
June 16, 2021
On CNBC's "Mad Money Lightning Round," Jim Cramer said it's a good opportunity to pick up some Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). The stock...
Via
Benzinga
< Previous
1
2
...
31
32
33
34
35
36
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.